Suzanne Trudel, MSc, MD

My area of research concerns new drug development for the treatment of mature B cell malignancies based on molecular targets. This encompasses drug discovery and pharmacological profiling of candidate compounds, pre-clinical studies to validate the target and determine potential therapeutic mechanisms of action, the establishment of appropriate animal models for drug testing, and the development of Phase I/II clinical trials.

Chromosomal translocations are present in approximately 50% of multiple myeloma patients and probably represent the first and defining genetic event that leads to the development of this disease. Characterization of these translocations has led to the identification of critical dysregulated oncogenes (FGFR3 and MMSET, c-maf and mafB, cyclin D1 and D3) that are potential molecular targets for anti-cancer agents.

We have recently validated FGFR3 as molecular therapeutic target in t(4;14) myeloma and have identified CHIR-258 as an active drug against FGFR3 expressing myeloma cells in pre-clinical studies. We are about to launch the first ever, clinical trial of FGFR3 inhibition in myeloma and are focusing our efforts on the development and implementation of relevant biological endpoints for this novel class of anti-tumor drug. Validation of additional molecular targets in myeloma such as MMSET and the maf and cyclin family of genes is also under development.
BMC Cancer. 2019 Aug 29;19(1):855
Benaniba L, Tessoulin B, Trudel S, Pellat-Deceunynck C, Amiot M, Minvielle S, Gourraud PA, de Visme S, Maisonneuve H, Lok A, Le Gouill S, Moreau P, Touzeau C
Inorg Chem. 2019 Jul 23;:
Lal G, Gelfand BS, Lin JB, Banerjee A, Trudel S, Shimizu GKH
Blood Cancer J. 2019 Mar 20;9(4):37
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD
ACS Appl Mater Interfaces. 2019 Apr 10;11(14):13069-13078
Banerjee A, Bertolesi GE, Ling CC, Blasiak B, Purchase A, Calderon O, Tomanek B, Trudel S
Ann Hematol. 2019 Jun;98(6):1441-1447
Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C
Ann Hematol. 2019 Jun;98(6):1435-1440
Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, Gastinne T, Bonnet A, Lok A, Lebourgeois A, Peterlin P, Garnier A, Chevalier P, Guillaume T, Thomaré P, Le Gouill S, Moreau P, Touzeau C
Clin Lymphoma Myeloma Leuk. 2018 Dec 20;:
Alahmadi M, Masih-Khan E, Atenafu EG, Chen C, Kukreti V, Tiedemann R, Trudel S, Reece DE
JAAD Case Rep. 2018 Nov;4(10):1052-1054
Devred I, Arnault JP, Adas A, Rea D, Lombart F, Sevestre H, Trudel S, Lok C, Chaby G
Lancet Oncol. 2018 Nov 12;:
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD



Associate Professor, Department of Medical Biophysics, University of Toronto